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H I G H L I G H T S
• PCSK9 acts by binding to the EGF-A domain of LDLR and promotes its degradation.
• Gain-of-function D374Y PCSK9 mutation causes severe hypercholesterolemia in humans.
• PCSK9-D374Y mediated LDLR degradation is inhibited by EGF-A analogs in vitro.
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A B S T R A C T
Background and aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low density lipoprotein
receptor (LDLR) through the LDLR epidermal growth factor-like repeat A (EGF-A) domain and induces receptor
internalization and degradation. PCSK9 has emerged as a novel therapeutic target for hypercholesterolemia.
Clinical studies with PCSK9 inhibiting antibodies have demonstrated strong LDL-c lowering effects, but other
therapeutic approaches using small molecule inhibitors for targeting PCSK9 functions may offer supplementary
therapeutic options. The aim of our study was to evaluate the effect of synthetic EGF-A analogs on mutated
(D374Y) PCSK9-D374Y mediated LDLR degradation in vitro.
Methods: Huh7 human hepatoma cells were transiently transfected to overexpress the gain-of-function D374Y
PCSK9 mutation, which has been associated with severe hypercholesterolemia in humans.
Results: Transient transfection of cells with PCSK9-D374Y expression vector very effectively enhanced de-
gradation of mature LDLR in Huh7. Treatment with both EGF-A and EGF-A truncated peptides inhibited this
effect and showed increased LDLR protein in Huh7 cells transfected with PCSK9-D374Y in a clear concentration
dependent manner. Huh7 transfected cells treated with increasing concentration of EGF-A analogs also showed
an increase internalization of labeled Dil-LDL.
Conclusions: The result of our study shows that EGF-A analogs are able to effectively hamper the enhanced
degradation of LDLR in liver cells expressing PCSK9-D374Y.
1. Introduction
PCSK9 (proprotein convertase subtilisin/kexin type 9) regulates LDL
cholesterol (LDL-C) levels by interacting with the LDL receptor (LDL-R)
[1–6]. Secreted mature PCSK9 binds the LDL-R on the surface of he-
patocytes and promotes their internalization and degradation in a post-
ER complex. PCSK9 catalytic activity is not required for LDL-R de-
gradation [1,4,7]. PCSK9 would function as a chaperone molecule that
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either prevents LDL-R recycling to plasma membrane from endosomes
and/or targets LDL-R to lysosome for degradation. The secreted form of
PCSK9 binds directly the extracellular domain (EGF-A domain) of LDL-
R. PCSK9 binding to this site is absolutely required for LDL-R de-
gradation [8]. Gain-of-function mutations (GOF) of PCSK9 cause hy-
percholesterolemia and early-onset coronary heart disease [9–12],
whereas loss-of-function mutations (LOF) result in low plasma choles-
terol levels and protection against coronary heart disease without ap-
parent negative consequences [13–15]. Therefore, inhibition of PCSK9
is being pursued as an approach to reduce plasma LDL cholesterol levels
[16].
Although the molecular mechanism of action of PCSK9 is not yet
completely clear, various approaches inhibiting the PCSK9/LDL-R
binding interaction have been investigated and developed.
Amongst those, inhibition by fully human PCSK9 antibodies (evo-
locumab and alirocumab) has been studied in a wide range of patients
and has shown to decrease LDL-C by ~50–70% [1]. Multiple phase 3
studies with these drugs have been already completed and the initial
data show a reduction of cardiovascular endpoints [17–19].
Both alirocumab and evolocumab have been approved in 2015 for
the treatment of hypercholesterolemia in the European Union and the
United States.
Alternative therapeutic strategies are directed at reducing produc-
tion of PCSK9 by antisense DNA [20] or RNA interference [21,22]
technologies. However, these therapeutic approaches are not the most
desirable for chronic asymptomatic conditions such as hyperlipidemia.
Small molecule inhibitors for targeting PCSK9 functions [23–26], may
offer potentially more convenient routes of administration and lower
costs.
Peptides are now emerging as therapeutic candidates to bridge the
gap between small-molecules (< 500 Da in mass) and large biologics,
including antibodies (> 5000 Da) [27]. A small peptide would be a
potential candidate to block the interaction between PCSK9 and the
LDLR.
In this study, we investigated the possibility of disrupting the
binding interface between LDL-R and the p.Asp374Tyr (D374Y) mu-
tated PCSK9 variant, able to increase its activity (gain of function,
GOF), by using in vitro two EGF-A analogs.
2. Materials and methods
2.1. Cloning and expression of PCSK9 cDNA
Huh7 cells were routinely cultured in Dulbecco's modified Eagle's
medium (DMEM, Gibco, Italy) supplemented with 10% fetal calf serum
(FCS), penicillin and streptomycin 100UI/ml, non essential amminoa-
cids (NEAA) 1% at 37 °C in a humidified 5% CO2 incubator.
Total RNA was isolated from Huh7 cells by using a RNA extraction
commercial kit following the manufacturer's instructions (RNAwiz™,
Ambion, Thermo Fisher Scientific, Italy).
2.2. Preparation of expression plasmids
Human full length wild type PCSK9 cDNA (GenBank NM_174936.2)
was amplified from Huh7 cells using a tailed pair of primers (PCSK9–F -
gcaagcttATGGGCACCGTCAGCTCCAG -3′ HindIII tailed and PCSK9-R′-
cactcgagCTGGAGCTCCTGGGAGGCCT -3′ XhoI tailed) in order to allow
the oriented cloning of the 2076 bp product into a C-terminal FLAG
tagging vector (pCMV-3Tag-8 Epitope Tagging Mammalian Expression
vector - Stratagene, La Jolla, CA, USA). The PCSK9 wild type (PCSK9-
WT) expression plasmid was purified by the Qiagen plasmid purifica-
tion maxi kit (Qiagen, Milano, Italy), and the sequence of the cloned
product was authenticated by direct sequencing in a 3500 Genetic
Analyzer and the results were analyzed with the Seqscape software
(both from Thermo Fisher, USA).
Biochemical and cellular analyses have revealed that the GOF
D374Y mutation originally observed by Timms et al. [28] results from a
10–25-fold higher affinity of PCSK9 for the LDLR [28–30]. This is the
most damaging GOF mutation of PCSK9, leading to severe hypercho-
lesterolemia and early death from premature coronary heart disease
[31].
The PCSK9-WT expression plasmid was used as template to prepare
mutant PCSK9-D374Y using the QuikChange II XL site-directed muta-
genesis kit (Stratagene, La Jolla, CA, USA). The mutagenic primers used
to introduce the D374Y (c.1120G > T) mutation were: PCSK9-
D374Y_F 5′- TGGTGCCTCCAGCTACTGCAGCACCTGCT - 3′ and PCSK9-
D374Y_R 5′- AGCAGGTGCTGCAGTAGCTGGAGGCACCA -3’ (the mu-
tated nucleotide is indicated in boldface and codons specifying for
amino acid change is underlined).
The mutant PCSK9-D374Y expression plasmid was purified and
authenticated as described above.
2.3. Synthetic EGF-A domain preparation
A 40mer synthetic peptide of EGF-A domain of LDLR (TNECLDN-
NGGCSHVCNDLKIGYECLCPDGFQLVAQRRCED) was custom-synthe-
sized and purchased from Genscript Corporation (USA). The guaranteed
peptide purity was> 85% by HPLC. An additional peptide corre-
sponding to the first 25aa of EGF-A peptide was custom synthesized
(P1- TNECLDNNGGCSHVCNDLKIGYECL) (Genscript Corporation,
USA). The guaranteed P1 peptide purity was 81.5% by HPLC.
2.4. Transient transfection of PCSK9-WT and PCSK9-D374Y in Huh7 cells
Huh7 cells were seeded at a density of 4.0× 105 cells/well 24 h
before transfection in a 24 wells plate (1.9 cm2/well) in DMEM-FCS
10%, penicillin and streptomycin 100UI/ml, non essential amminoacids
(NEAA) 1%.
At a cell confluence of 70%, plasmid vectors containing either
PCSK9-WT or mutant PCSK9-D374Y cDNA were transfected into Huh7
cells with Lipofectamine 2000 (Invitrogen, USA) according to manu-
facturer's instructions.
Thirty hours after transfection, Huh7 cells were treated with serum
free media or media containing EGF-A and P1 peptides at concentration
of 12, 5 μM, 25 μM and 50 μM for 18 h.
In a subset of experiments, transfected cells with mutant PCSK9-
D374Y cDNA were treated with alirocumab at a final concentration of
19.2 μg/mL as previously described [32].
After 18 h incubation cells were harvested and lysed in Ripa Buffer
(NaCl 150mM, 1% NP40, 0, 5% Na-deoxycholate, 0, 1% SDS, 50mM
TRIS ph 8).
Quantification of total proteins of whole-cell lysate from Huh7 cells
was performed by BCA micro protein assay kit (Pierce Biotechnology,
Rockford, IL, USA).
2.5. Western blot analysis
Twenty μg of total proteins from cell lysates were suspended in
Laemmli Sample Buffer (0.5 mM pH 6.8 Tris-HCl, 10% SDS, 20% gly-
cerol and 0.3% bromophenol blue) (1:1) and DTT (0, 3 μl/10 μl), heated
to 95 °C for 5min and separated by linear 10% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) in a NuPage MES SDS Running Buffer 20x
(Invitrogen, USA) at 180mA. Cell lysates and media proteins were
electro-transferred from the gel to a PVDF (polyvinylidene fluoride)
membrane Hybond P (GE Healthcare Bio-Sciences AB, Uppsala,
Sweden) according to the manufacturer's instructions. The transfer was
performed in a refrigerator at 35V (constant voltage) for 2 h. The
membrane was incubated with 5% non-fat dry milk in PBS containing
0.05% of Tween-20 (blocking solution) at room temperature to block
non-specific binding of the antibodies.
After 1 h incubation, the membrane was cut into two sections to be
incubated with different antibody: the upper section (spanning from
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100 kDa to 250 kDa) was incubated with anti-human LDL Receptor
rabbit polyclonal antibody (Progen Biotechnik GmbH, Heidelberg,
Germany) in PBS Buffer with 2% of non-fat dry milk and 0.05% of
Tween-20, with a 1:500 ratio; the lower section (spanning from
~20 kDa to ~60 kDa) was incubated either with anti-human β-Actin
mouse monoclonal antibody (Sigma, USA) or α-tubulin mouse mono-
clonal antibody (Santa Cruz, USA) in PBS Buffer with 2% of non-fat dry
milk and 0.05% of Tween-20, with a 1:20,000 ratio for β-Actin and
1:250 ratio for α-tubulin.
After overnight incubation with primary antibodies at 4 °C, the two
sections were washed twice with 0.1% Tween-20 in PBS Buffer. The
upper section was incubated with Anti-Rabbit IgG (Sigma, USA) diluted
in PBS Buffer with 5% non-fat dry milk and 0.05% Tween-20, with a
1:5000 ratio. The lower section was incubated with Anti-Mouse IgG
(Sigma, USA) diluted in PBS Buffer with 5% non-fat dry milk and 0.05%
Tween-20, with a 1:20.000 ratio. Immunocomplexes were detected by
ECL plus Western Blotting Detection Kit (GE Healthcare Bio-Sciences
AB, Uppsala, Sweden) followed by autoradiography.
2.6. LDL internalization assay
Thirty hours after transfection with PCSK9-D374Y and empty vec-
tors, Huh7 cells were treated with EGF-A and P1 peptides in increasing
concentrations (12, 5 μM, 25 μM and 50 μM) in serum-free D-MEM.
After 14 h cells were then treated with, 40 μg/μl of Dil-LDL as de-
scribed elsewhere [33].
Quantification of total protein content in each well was performed
by BCA micro (Pierce Biotechnology, Rockford, IL, USA). Then whole
cell extracts were analyzed at 520 nm and 570 nm by using the
VICTOR™ X4 fluorimetric System (PerkinElmer Life Sciences) to mea-
sure fluorescent signal from internalized Dil-LDL. The results were
normalized with respect to the total protein content. Results were ex-
pressed as percent of the Dil-LDL binding without competitors. All ex-
periments were performed in triplicate.
2.7. Statistics
The internalization curve has been fitted using a Michaelis Menten
first degree equation with a linear non specific component (see also
supplementary methods); the values of dissociation constant (kd) and
maximum amount (Bmax) of internalized LDL were evaluated together
with the non specific internalization constant (klin) using a non-com-
partmental approach included in the SAAM II ver 1.0 software from
RFKA (Seattle, USA).
3. Results
We evaluated whether a synthetic EGF-A domain of LDLR could
inhibit LDLR degradation mediated by blocking its interaction with a
D374Y PCSK9 mutant, so to restore LDL uptake using Huh7 liver cells as
a model system.
Transient transfection of cells with PCSK9-WT and PCSK9-D374Y
expression vectors enhanced degradation of mature LDLR in Huh7
compared to cells transfected with empty vector with a more marked
effect in cells treated with the mutant PCSK9-D374Y vector (Fig. 1A and
B; Fig. 2A and C).
The presence of EGF-A inhibited this effect and showed increased
LDLR protein in Huh7 cells transfected with PCSK9-WT and PCSK9-
D374Y. The inhibition was effective both in the Huh7 expressing
PCSK9-WT and PCSK9-D374Y at 12.5 μM EGF-A, showing a clear con-
centration dependent increase at 25 and 50 μM EGF-A (Fig. 1A and B,
Fig. 2A and C). In a parallel experiment, the treatment of PCSK9-D374Y
transfected cells with the P1 synthetic peptide was also able to inhibit
the mature LDLR degradation in a concentration dependent manner
(12.5–50 μM). (Fig. 2B and C).
As control, we also tested the effect of treatment with alirocumab in
cells transfected with PCSK9-D374Y. In this setting the inhibition of
LDL-R degradation appeared less pronounced than EGFA treated cells
(Fig. 3A and B).
EGF-A and P1 peptides inhibition of D374Y-PCSK9 function was
further assayed by internalization of Dil-labeled LDL. Huh7 transfected
cells treated with increasing concentration of both EGF-A and P1 pep-
tides, showed an efficient inhibition of the LDL-R and D374Y binding
affinity demonstrated by increase internalization of Dil-LDL (Fig. 4 and
Supplemental Fig. 1).
4. Discussion
PCSK9 is a validated target for the treatment of hypercholester-
olemia. Monoclonal antibodies (MAbs) that bind to PCSK9 and prevent
PCSK9 interaction with LDL-R have been shown to reduce circulating
LDL-C levels in pre-clinical animal models and in human clinical trials.
The discovery of small molecules that can disrupt the interaction of
PCSK9 with LDL-R has prompted to the identification of alternative
approaches for antagonizing PCSK9 function.
Shan et al. were the first to show that, the induced degradation
mediated by the PCSK9-LDL-R interaction is effectively inhibited by the
presence in the cell media of a synthetic EGF-A domain peptide in
PCSK9 treated HepG2 cells, and this effect resulted in increased LDL-R
protein and LDL uptake [23].
Aspartic acid at position 374 in PCSK9 protein (D374) is crucial for
binding the EGF-A domain of LDL-R; the GOF D374Y mutation confers
higher affinity of PCSK9 for the LDL-R and this result in enhanced re-
ceptor degradation and severe hypercholesterolemia in humans
[29–31].
Mutations in EGF-A have been also linked to familial hypercholes-
terolemia. In particular, the gain-of-function mutation p.His327Tyr
(H327Y) in EGF-A is associated with increased pH-independent binding
affinity for PCSK9 by forming a hydrogen bond with D374 in PCSK9
[25].
In our study, we investigated the possibility of inhibiting the in-
teraction of PCSK9-D374Y GOF mutation with mature LDL-R, and
promoting the internalization of labeled LDL-C by using both a syn-
thetic full length EGF-A domain peptide and a 25-amino acid truncated
EGF-A analog in a cell-based assay.
To pursue this objective we decided to transiently express PCSK9-
D374Y in Huh7 and we next added in the medium a synthetic full
length EGF-A domain peptide. A similar set of experiments were per-
formed by adding a shorter 25-amino acid truncated EGF-A analog.
Both peptides were able to inhibit the degradation of mature LDL-R
mediated by PCSK9-D374Y and the inhibition of PCSK9-D374Y activity
was reflected in a corresponding increase in Huh7 uptake of Dil-labeled
LDL.
In our in vitro system the treatment with EGF-A analogs appeared to
be more effective in the inhibition of the degradation of LDL-R com-
pared to the treatment with monoclonal antibody against PCSK9 (alir-
ocumab).
Schroeder et al. have previously shown that truncated EGF-A pep-
tides restore LDL-R recycling in the presence of PCSK9 in vitro [34].
They elegantly showed that the smallest part of the EGF-A domain
(EGF-A5) retains binding affinity similar to that of wild type EGF-A, but
had a weaker potency to inhibit PCSK9-driven LDL-R as shown by
functional assays [34]. A mutated peptide H306Y was able to promote
increase binding affinity through a hydrogen bond with D374 in PCSK9
[34].
These studies are consistent with our data suggesting that the
binding between PCSK9 and LDL-R can be modulated by peptides ad-
ministration and that our therapeutic approach is suitable for patients
affected by familial hypercholesterolemia due to GOF mutations in
PCSK9 gene.
Recently, the discovery of peptides competitive with EGF-A binding
to PCSK9 has progressed and the identification of a lupin derived
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decapeptide [35] and an imidazole-based peptidomimetic [36] are
some examples. Zhang et al. by screening linear and di-sulfide linked
phage displayed peptides libraries identified potent PCSK9 inhibitors
[37]. The most promising peptide was a 13 amino acid long peptide
binding to PCSK9; this short peptide structurally overlap with the EGF-
A binding site and is therefore competing with the EGF-A domain with a
similar mode of action as the monoclonal antibodies [37]. More
recently, the same research group reported on the discovery of a tar-
getable cryptic N-terminal groove in PCSK9 very close to the EGF-
A–PCSK9 interaction surface [38]. They identified an optimized peptide
that was also able to restore LDL-R in HepG2 cells by combining phage
display experiments and a structure guided design [38].
Additional functional domains in other parts of the PCSK9 protein
have been identified and have not been reported yet. As an example, it
Fig. 1. EGF-A peptide inhibits WT PCSK9-mediated degradation of LDLR.
(A) Huh7 cells were transiently transfected with PCSK9-WT expression plasmid and empty vector (control) and treated with EGF-A at 12,5 μM, 25 μM and 50 μM as
indicated in the Methods section. Whole cell protein lysates were prepared and duplicate samples analyzed for LDLR protein by Western blotting. The band
corresponding to mature LDLR (160 kD) is indicated. (B) The amount of total LDLR protein relative to the amount of α-tubulin is shown. Results are expressed as
percentage of LDLR protein relative to control cells transfected with empty vector. Error bars are standard deviation of duplicate experiments.
Fig. 2. EGF-A and truncated EGF-A peptides inhibit D374Y PCSK9-mediated degradation of LDLR.
(A and B) Huh7 cells were transiently transfected with mutant PCSK9-D374Y expression plasmid and empty vector (control) and treated with EGF-A at 12,5 μM,
25 μM and 50 μM (A) or truncated EGF-A peptide (P1) at 12,5 μM, 25 μM and 50 μM (B) as indicated in the Methods section. Whole cell protein lysates were prepared
and duplicate samples analyzed for LDLR protein by Western blotting. The band corresponding to mature LDLR (160 kD) is indicated. (C) The amount of total LDLR
protein relative to the amount of β-actin is shown. Results are expressed as percentage of LDLR protein relative to control cells transfected with empty vector. Error
bars are standard deviation of duplicate experiments.
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has recently been reported that PCSK9 binding to proteoglycans is
important for PCSK9-LDL-R binding, suggesting that the block of the
PCSK9-proteoglycans interaction may represent an additional oppor-
tunity for small PCSK9 inhibitors [39].
Despite the progresses in understanding the PCSK9-LDL-R interac-
tion at the molecular level and in identifying smaller peptides and
peptidomimetics able to inhibit this interaction, needs to be said that
the achievement of an oral drug with this mode of action remains a
challenge.
In conclusion, the result of our study shows that EGF-A analogs are
able to effectively hamper the enhanced degradation of LDL-R in liver
cells expressing a gain of function mutation of PCSK9-D374Y re-
sponsible for FH in some patients. The identification of a small peptide
of 25 aa able to work as the whole EGF-A might allow in the future to
imagine an oral administration of the drug by using up-to-date nano-
technologies.
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